NAD Refers Advertising for That’s Natural’s CBD Hemp Oil to FTC, FDA for Further Review

New York, NY – April 24, 2018 – The National Advertising Division has referred advertising claims made by That’s Natural, Ltd., to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for further review, after the company failed to respond to NAD’s request to provide substantiation the advertising claim that CBD Hemp Oil “makes cancer cells commit ‘suicide’ without killing other cells.”

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

The policies and procedures governing self-regulation provide that when an advertiser elects not to participate in a review of its claims, NAD “shall prepare of a review of the facts with relevant exhibits and forward them to the appropriate federal or state law enforcement agency.”

Here, following the advertiser’s failure to respond to NAD’s inquiry, the advertising at issue will be referred to the FTC and FDA for further review.

Note: A recommendation by NAD to modify or discontinue a claim is not a finding of wrongdoing and an advertiser’s voluntary discontinuance or modification of claims should not be construed as an admission of impropriety. It is the policy of NAD not to endorse any company, product, or service. Decisions finding that advertising claims have been substantiated should not be construed as endorsements.